MARKET

BGNE

BGNE

BeiGene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

388.51
-9.99
-2.51%
After Hours: 388.51 0 0.00% 17:06 09/21 EDT
OPEN
399.93
PREV CLOSE
398.50
HIGH
405.12
LOW
387.25
VOLUME
220.30K
TURNOVER
--
52 WEEK HIGH
426.56
52 WEEK LOW
219.20
MARKET CAP
36.15B
P/E (TTM)
-26.6168
1D
5D
1M
3M
1Y
5Y
2 Outperforming Biotech Stocks to Examine on Covid-19 Vaccine Updates
GuruFocus News · 14h ago
BRIEF-Beigene Announces Inclusion In FTSE Russell Indices
reuters.com · 1d ago
BeiGene Announces Inclusion in FTSE Russell Indices
CAMBRIDGE, Mass. & BEIJING, September 20, 2021--BeiGene announced inclusion in several FTSE Russell indices.
Business Wire · 1d ago
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
Benzinga · 1d ago
Why BeiGene Shares Are Rising
Beigene Ltd (NASDAQ: BGNE) shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults with Waldenström's macroglobulinemia.
Benzinga · 4d ago
Why These 10 Stocks Are On the Move on Friday
In this article we will take a look at the some of notable stocks on the move today. You can skip our detailed analysis of these stocks and go to read Why These 5 Stocks Are On the Move on Friday It’s another red day on Wall Street with all three major ind...
Insider Monkey · 4d ago
Hot Stocks: CREE downgrade, CNC rumors; FORG keeps rising; CURI climbs on positive comment
Friday's midday action saw its share of bright spots despite weakness in the overall markets. Gainers included Centene (NYSE:CNC), which climbed in the wake of takeover speculation. Meanwhile, ForgeRock (NYSE:FORG) continued
Seekingalpha · 4d ago
25 Stocks Moving In Friday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 92.7% to $17.35 after the company announced its media unit has entered into an agreement with FOX Networks to broadcast the Italian Serie B championship across the USA and the Caribbean.
Benzinga · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BGNE. Analyze the recent business situations of BeiGene through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BGNE stock price target is 402.29 with a high estimate of 514.00 and a low estimate of 248.35.
EPS
Institutional Holdings
Institutions: 355
Institutional Holdings: 64.57M
% Owned: 69.41%
Shares Outstanding: 93.04M
TypeInstitutionsShares
Increased
105
849.54K
New
31
273.92K
Decreased
76
1.49M
Sold Out
16
33.69K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Director
John Oyler
President/Chief Operating Officer/General Manager
Xiaobin Wu
Co-Founder/Non-Executive Director
Xiaodong Wang
Chief Financial Officer
Julia Wang
Other
Jane Huang
Secretary
Hing Ling Chau
Non-Executive Director
Anthony Hooper
Non-Executive Independent Director
Timothy Chen
Non-Executive Independent Director
Donald Glazer
Non-Executive Independent Director
Michael Goller
Non-Executive Independent Director
Ranjeev Krishana
Non-Executive Independent Director
Thomas Malley
Non-Executive Independent Director
Corazon Sanders
Non-Executive Independent Director
Jing-Shyh Su
Non-Executive Independent Director
Qingqing Yi
No Data
About BGNE
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Webull offers kinds of Beigene Ltd (ADR) stock information, including NASDAQ:BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.